ArticleScientific reports2025
Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Consolidative versus salvage stereotactic ablative radiotherapy to the primary lung tumor in stage IV non-small cell lung cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) with EGFR mutations presents a unique challenge due to the development of oligometastasis during treatment with first-line tyrosine kinase inhibitors (TKIs). The optimal timing of radiotherapy in EGFR-mutant oligometastatic NSCLC remains debated. This study aims to investigate the timing of radiotherapy in relation to disease progression to optimize treatment outcomes. We conducted a retrospective analysis of stage IIIB-IV EGFR-mutant NSCLC patients who received first-line TKI therapy and developed oligoprogressive disease between January 2019 and October 2024. Two groups were compared: one receiving radiotherapy before disease progression (n = 41) and the other post-progression (n = 26). The primary outcomes were progression-free survival (PFS1), progression-free survival after radiotherapy (RT-PFS), and the duration of first-line TKI therapy. Statistical analyses were performed using Kaplan-Meier curves and Cox regression. A total of 67 patients were included. The median PFS1 was 13.8 months in the upfront consolidative radiotherapy group versus 9.8 months in the post-progression group (P = 0.391). The median duration of first-line TKI therapy was significantly longer in the post-progression radiotherapy group (20.3 months vs. 13.3 months, P < 0.001). Kaplan-Meier survival analysis showed a significant difference in TKI duration, suggesting delayed radiotherapy improved TKI duration. This retrospective study suggests that the timing of radiotherapy may influence the duration of first-line EGFR-TKI therapy in patients with oligometastatic NSCLC. Administering local therapy at the time of oligoprogression may help prolong TKI benefit without premature treatment escalation. However, given the study's retrospective design and potential baseline imbalances, these findings should be interpreted with caution and require validation in future prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.